[Current usage of molecular targeting drugs].
Sugio
Kenji
K
Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Minami-ku, Fukuoka, Japan
D000906:Antibodies / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D040262:Receptors, Vascular Endothelial Growth Factor / Q000276:immunology
D000906:Antibodies; D004791:Enzyme Inhibitors; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor